Corbus Pharmaceuticals Announces Initiation of Phase 2 Study of Anabasum for Treatment of Systemic Lupus Erythematosus December 22, 2017
Corbus Pharmaceuticals Holdings, Inc. Announces Exercise of Option to Purchase Additional Shares in Public Offering November 27, 2017
Corbus Pharmaceuticals Expands Intellectual Property Portfolio with Patent Issuance Covering the Use of Anabasum for the Treatment of Rare Fibrotic Diseases November 27, 2017
Corbus Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference November 15, 2017
Corbus Pharmaceuticals Reports 2017 Third Quarter Financial Results and Highlights Recent Corporate and Clinical Advancements November 8, 2017
Corbus Pharmaceuticals Reports Significant Improvement in mRSS and Other Clinical Outcomes at 28-Weeks in Systemic Sclerosis Open-Label Extension of Phase 2 Study November 6, 2017
Corbus Pharmaceuticals Announces New Patent Issuance Covering the Use of Anabasum for the Treatment of Inflammatory Diseases October 31, 2017
Corbus Pharmaceuticals Holdings, Inc. Prices Underwritten Public Offering of Common Stock October 24, 2017
Corbus Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering of Common Stock October 23, 2017
Corbus Pharmaceuticals Reports Positive Topline Results from Phase 2 Study in Rare Autoimmune Disease Dermatomyositis October 19, 2017
Corbus Pharmaceuticals Announces Presentation of Three Abstracts at the 2017 North American Cystic Fibrosis Conference September 25, 2017
Corbus Pharmaceuticals Announces Presentation of Six Abstracts and New Anabasum Data at 2017 ACR Annual Meeting September 20, 2017
Corbus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference September 14, 2017
Corbus Pharmaceuticals to Host Fireside Chat on Dermatomyositis with Expert Physician and Researcher, Victoria Werth, MD August 31, 2017
Corbus Pharmaceuticals Reports 2017 Second Quarter Financial Results and Provides Business Update August 9, 2017
Corbus Pharmaceuticals to Present New Data from Systemic Sclerosis Phase 2 Study of Anabasum at the 15th International Workshop on Scleroderma Research August 7, 2017
Corbus Pharmaceuticals Presented Data from Phase 2 Study of Anabasum for the Treatment of Systemic Sclerosis at the EULAR 2017 Annual Meeting June 15, 2017
Corbus Pharmaceuticals to Present Data from Phase 2 Study of Anabasum at the European Cystic Fibrosis Society 2017 Conference June 8, 2017
Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Anabasum for the Treatment of Skin-Predominant Dermatomyositis May 11, 2017
Corbus Pharmaceuticals Reports 2017 First Quarter Financial Results and Provides Business Update May 9, 2017
Corbus Pharmaceuticals to Commence Single Phase 3 Study of Anabasum for Treatment of Systemic Sclerosis Following Guidance Received from Successful End-of-Phase 2 Meeting with FDA April 5, 2017
Corbus Pharmaceuticals Reports Positive Topline Data Demonstrating Anabasum Reduces Acute Pulmonary Exacerbations and Multiple Inflammatory Biomarkers in Phase 2 Study in Patients with Cystic Fibrosis March 30, 2017
Corbus Pharmaceuticals Reports 2016 Financial Results and Provides 2017 Business Update March 9, 2017
Corbus Pharmaceuticals to Present Gene Expression Data from Recent Phase 2 Systemic Sclerosis Study Demonstrating JBT-101 Inhibits Inflammation and Fibrosis Pathways March 8, 2017
Corbus Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference March 1, 2017
Corbus Pharmaceuticals Announces Preclinical Data Demonstrating JBT-101 Reduces Inflammation in Alveolar Macrophages from Cystic Fibrosis Patients February 23, 2017
Corbus Pharmaceuticals Receives Orphan Designation for JBT-101 for the Treatment of Systemic Sclerosis in the European Union January 17, 2017
